Pfizer’s Braftovi (encorafenib) combination therapy was shown to reduce the risk of death by nearly half compared to standard of care (SOC) for metastatic colorectal cancer (mCRC) patients with BRAF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback